Val Gebski
机构: NHMRC Clinical TRials Centre, University of Sydney
每年引用次数
引用次数
引用: 63,460
H-指数: 98
I10-指数 : 352
出版物: 760
Variability in estimating late normal tissue toxicity for patients receiving radiotherapy. Does experience influence what we are telling our patients
T.P. Shakespeare , M.K. Dwyer , R. Mukherjee , R. Yeghiaian-Alvandi
European Journal of Cancer 37
2001
Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.
F.T. Roncolato , E. Gibbs , C.K. Lee , R. Asher
Annals of Oncology 28 ( 8) 1849 -1855
16
2017
Adjusting the significance level of the final analysis with multiple interim analysis and fixed sample size
J.L. Baker , R.J. Simes , I.M. Arulchelvam , V.J. Gebski
Controlled Clinical Trials 19 ( 3)
1998
Estimating treatment effects in an unbalanced two period cross-over trial with poisson outcomes
A.D. Lunn , V.J. Gebski
Controlled Clinical Trials 19 ( 3)
1998
Disease-Free and Overall-Survival After Total Laparoscopy Versus Open Abdominal Hysterectomy for Early Stage Endometrial Cancer: Results From the Lace Trial
V. Gebski , P. Forder , M. Laney , D. Neesham
International Journal of Gynecological Cancer 26 ( 2) 9 -10
1
2016
QUALITY OF LIFE ASSESSMENT IN EARLY-STAGE CERVICAL CANCER PATIENTS IN UNDERGOING RADICAL HYSTERECTOMY VIA MINIMALLY INVASIVE SURGERY OR OPEN APPROACH: THE LACC TRIAL
M. Frumovitz , V. Gebski , P. Ramirez , R. Pareja
International Journal of Gynecological Cancer 28 4 -4
2018
Decision models for valuing effectiveness of new diagnostic technologies
V. Gebski , Harold Hudson , S. Lord , Zhixin Liu
Macquarie Statistics Research Papers 28 1 -3
2004
Solugel versus silver sulphadiazine cream in the treatment of radiation-induced moist desquamation
V. Gebski , John Boyages , A Gamble
Primary Intention 6 ( 3) 102 -107
1
1998
0284: Presenting Symptoms of Epithelial Ovarian Cancer
I. M. Lataifeh , D. E. Marsden , N. Hacker , V. Gebski
International Journal of Gynecologic Cancer 16
2006
Pegylated liposomal doxorubicin (PLD)-carboplatin (C) (C-D) vs paclitaxel-carboplatin (C-P) in relapsing sensitive ovarian cancer (OC): A 500-patient interim safety analysis of the CALYPSO GCIG Intergroup phase III study
E. Åvall-Lundqvist , P. Wimberger , L. Gladieff , V. Gebski
Journal of Clinical Oncology 26 5565 -5565
4
2008
International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial
T. J. Price , V. Gebski , G. A. van Hazel , B. A. Robinson
Journal of Clinical Oncology 26 4029 -4029
12
2008
Engaging Future Clinical Oncology Researchers: An Initiative to Integrate Teaching of Biostatistics and Research Methodology into Specialty Training.
S Turner , P Sundaresan , K Mann , D Pryor
Clinical Oncology 28 ( 5) 306 -316
5
2016
Long Term Patient Reported Urinary Function Following External Beam Radiotherapy for Prostate Cancer
S. Chin , A.J. Hayden , V. Gebski , S. Cross
Clinical Oncology 29 ( 7) 421 -428
4
2017
Basic treatment equivalent (BTE) — a better measure of linear accelerator workload
G. Delaney , V. Gebski , B. Jalaludin , S. Griffiths
European Journal of Cancer 37
2001
Combining components of quality of life to increase precision and evaluate trade-offs.
T. Lumley , R. J. Simes , V. Gebski , H. M. Hudson
Statistics in Medicine 20 ( 21) 3231 -3249
11
2001
Outcomes of first-line chemotherapy for advanced breast cancer in women with good versus poor quality of life at baseline
C. Lee , M. Stockler , V. Gebski , A. Coates
Journal of Clinical Oncology 27 1036 -1036
2009
International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial
N. C. Tebbutt , V. Gebski , K. Wilson , M. Cummins
Journal of Clinical Oncology 27 4023 -4023
11
2009
Response to the Letters to the Editor sent by (1) Kundi, (2) Goldstein/Kheifets/van Deventer/Repacholi, and (3) Lerchl
T. D. Utteridge , V. Gebski , J. W. Finnie , B. Vernon-Roberts
Radiation Research 159 ( 2) 277 -278
9
2003
Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
I. N. Olver , , P. Grimison , M. Chatfield
Supportive Care in Cancer 21 ( 6) 1561 -1568
18
2013
A Novel Technique of Continuous Parasternal Ropivacaine Infusion after Cardiac Surgery: Background Study to the PAINLESS Trial
A. Kiat , R. Dignan , V. Gebski , A. Keech
Heart Lung and Circulation 19 ( 19)
2010